BioNano Genomics (BNGO) Price & Analysis
BNGO Stock Chart & Stats
- Day’s Range
- MXN 69.35 - MXN 69.35
- 52-Week Range
- MXN 69.35 - MXN 69.35
- Previous Close
- MXN 69.35
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 301.96M
- Enterprise Value
- MXN 9.33M
- Total Cash (Recent Filing)
- MXN 9.92M
- Total Debt (Recent Filing)
- MXN 6.70M
- Price to Earnings (P/E)
- ―
- Beta
- -0.33
- Next Earnings
- Nov 10, 2026
- EPS Estimate
- -8.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Growth
Strong consumable growth and higher utilization at existing customer sites support a more recurring revenue model than instrument sales alone. As the installed base expands, ongoing sample processing can increase revenue visibility, deepen customer retention, and improve the platform’s economic attractiveness.
Clinical Adoption And Reimbursement
Clinical evidence showing OGM can identify abnormalities missed by traditional methods strengthens its value proposition in diagnostic workflows. Established CPT codes and draft Medicare coverage create structural reimbursement support that can reduce adoption barriers and expand the addressable clinical market.
Improving Gross Margin
The sharp improvement in gross margin indicates better economics as the business shifts toward consumables and higher-value recurring activity. If sustained, stronger unit profitability can support reinvestment, reduce the cash required to fund growth, and improve the path toward eventual operating breakeven.
Bears Say
Persistent Cash Burn
The core business remains unable to fund itself, with substantial operating and free-cash-flow deficits despite improvement from earlier periods. Continued cash consumption limits financial flexibility and makes future operations dependent on additional capital access, cost reductions, or a faster transition to profitability.
Deep Ongoing Losses
Severe ongoing losses show that revenue growth and margin improvement have not yet translated into a sustainable earnings model. Persistent unprofitability erodes equity, limits internally funded investment, and increases the risk that future financing or restructuring will be needed to support the business.
Manufacturing Capacity Constraints
Capacity constraints prevent the company from fully converting demonstrated consumable demand into near-term sales. Backorders can delay customer workflows, constrain installed-base utilization, and defer revenue recognition, while unresolved limits may weaken commercial momentum until production capability catches up.
BNGO FAQ
What was BioNano Genomics’s price range in the past 12 months?
What is BioNano Genomics’s market cap?
When is BioNano Genomics’s upcoming earnings report date?
How were BioNano Genomics’s earnings last quarter?
Is BioNano Genomics overvalued?
Does BioNano Genomics pay dividends?
What is BioNano Genomics’s EPS estimate?
How many shares outstanding does BioNano Genomics have?
What happened to BioNano Genomics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioNano Genomics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioNano Genomics
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert A. Luderer
- Employees
- 96
- Website
- bionano.com
- Address
- 9540 Towne Centre Drive, San Diego, CA, 92121, US
BioNano Genomics (BNGO) Earnings & Revenues
BNGO Company Deck
BNGO Earnings Call
Earnings Call SentimentPositive
The call conveyed strong execution on key commercial and clinical fronts: double-digit revenue growth, record flow-cell sales, a shift to higher-margin consumable revenue, improved gross margins (53%), significant clinical publications validating OGM, and the retirement of convertible debt. These positives were tempered by operational constraints — notably manufacturing capacity and backorders — a modest cash balance with runway into early 2027, and a YoY decline in software revenue. Management raised the low end of full-year guidance but remained cautious on the upside until supply constraints are resolved.
View all MX:BNGO earnings summariesBNGO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 7 |
| Technical Analysis | 0 | 1 | 1 |
| Moving Averages | 2 | 4 | 6 |